Lupus presents unique challenges, particularly for patients with lupus nephritis — a severe form of the condition that affects kidney function and quality of life. Current treatments often come with side effects and limited effectiveness, leaving patients in need of better options. At Worldwide, we’re working to accelerate the future of lupus treatments by focusing on innovative, targeted, and more tolerable therapies, utilizing our global reach across 70+ countries, strong partnerships, and commitment to patient-centered research.
Worldwide’s Approach to Lupus Research
Our team at Worldwide knows that success in lupus research requires more than just cutting-edge science. It’s about people — the patients we serve and the experts we work with. That’s why we partner with organizations like the Lupus Foundation of America and the Lupus Research Alliance, which helps us recruit and support patients effectively. Our deep understanding of autoimmune diseases and dedication to quality allow us to deliver a research approach that’s as compassionate as it is rigorous. With our patient-first mindset and extensive experience, we’re bringing meaningful change to lupus trials.
Driving Innovation in Lupus Treatments
Today’s lupus treatment landscape is rapidly evolving, with advances like biologics, immunomodulators, gene therapy, and personalized medicine showing great promise. At Worldwide, we’re here to support these breakthroughs. For instance, in a recent Phase III lupus study, we used advanced technology through our Clinical Assessment Training and Surveillance (CATS) to monitor systemic lupus erythematosus (SLE) disease activity in real time — a critical measure of treatment success.
Addressing Challenges in Lupus Trials
Lupus trials often face several obstacles, such as patient recruitment, disease variability, and endpoint management. But at Worldwide, we’re well-equipped to handle these challenges. We start with a strategic feasibility analysis to pinpoint the best countries and sites for recruitment. In high-prevalence areas like Latin America and Asia-Pacific, our local teams and strong partnerships with advocacy groups help us recruit and engage patients effectively.
We also understand the unique needs of lupus trials. For instance, in SLE trials, we manage appropriate training and adjudication of the lupus scales used as eligibility and/or endpoints, otherwise the focus is only on lupus nephritis. In lupus nephritis studies, we manage flare timing and fast-track biopsy procedures, allowing us to select and retain patients who meet the specific trial requirements. Our experience in handling these nuanced details enables us to meet recruitment goals and deliver quality data, ensuring study success from start to finish.
Looking Ahead: A Vision for the Future
Our vision is to build a future where lupus treatments are safer, more effective, and truly patient-centered. We’re committed to expanding our partnerships, diversifying patient recruitment through digital outreach, and supporting therapies that could redefine lupus care. As we continue to power the future of lupus treatments, we invite you to learn more about our work in autoimmune research and discover how we’re changing the landscape of lupus care.
Contact us to discuss how we can support your lupus study needs and help advance your research.
